3 Excellent Reasons To Plough Your Cash Into GlaxoSmithKline plc

Royston Wild describes why GlaxoSmithKline plc (LON: GSK) is a great pick for strong returns.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gsk

Today I am highlighting three great reasons to buy into pharmaceutical giant GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

Pipeline pumping out revenue grabbers

Although the pharmaceutical sector has been hammered by the effect of patent expirations in recent times, GlaxoSmithKline’s pre-emptive decision to invest heavily in R&D is clearly paying off handsomely. The firm’s 2013 results released last week showed revenues rise 1% to £26.5bn and pre-tax profits advance 0.7% to £6.6bn.

The firm rolled out a multitude of new products across its identified growth areas of Respiratory, Vaccines, HIV and Oncology last year. It also received approval for six new drugs in 2013, and completed regulatory filing procedures for another five. These are figures that GlaxoSmithKline’s main rivals can only dream of.

With the company planning to introduce up to 30 new Consumer Healthcare brand innovations in 2014, and Phase III testing on 10 new drugs scheduled to commence over the next two years, I expect turnover to ignite in the coming years.

Growth markets illustrate plump earnings prospects

Allegations of widescale corruption in China continue to weigh on group performance, however. Pharmaceutical and vaccine sales in the country fell 29% during the fourth quarter, even though this signalled a vast improvement on the 61% collapse in July-September.

Question marks remain over how much longer the probe into GlaxoSmithKline’s conduct is set to last, while the hard line adopted by the Chinese authorities has caused many to worry about severe consequences for the firm. Still, I am convinced that GlaxoSmithKline’s position as a critical drugs supplier in the country will result in little more than a slap on the wrist.

Instead, I believe that investors should be concentrating on the huge success that the company is making in potentially lucrative emerging markets. Even taking into account the persistent problems in China, turnover in the EMAP (Emerging Markets Asia Pacific) region advanced 5% to £1.3bn in September-December. And I believe sales will be set to stride in this territory once the current misconduct case in China is resolved.

A deft dividend selection

GlaxoSmithKline is a long-standing favourite with dividend seekers owing to its hugely-generous dividend policy. This was underlined in last week’s results when the firm elected to raise the full-year dividend 5.4% to 78p per share.

And City analysts expect the payouts to keep on rolling, with a 4.4% lift forecast for 2014 to 81.4p and a further 6.4% rise anticipated for next year, to 86.6p. These figures spawn giant dividend yields of 5.2% and 5.5% for these years, comfortably surpassing the 3.2% FTSE 100 forward average and smashing a corresponding reading of 2.4% for the complete pharmaceuticals and biotechnology space.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Royston does not own shares in GlaxoSmithKline. The Motley Fool has recommended GlaxoSmithKline.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »